Australian drug manufacturer Mesoblast has been given the go-ahead signal by the European Medicines Agency to conduct a trial for its stem cell injection, Revascor, which promises to provide more efficient treatment for patients who have suffered from acute heart attacks.
Revascor has been developed using stem cells extracted from the bone marrow of healthy young adults and the company said that initial studies have shown the injection to reduce the damage caused by heart attacks by more than 50 percent.
AdvertisementThe company has been given clearance to conduct the trial in Europe with 225 patients expected to take part in the study including those from Belgium, England and the Netherlands.
Mesoblast revealed that it expected the product to hit the market within the next five years.
P FDA Advisory Panel to Re-Evaluate Popular Osteoporosis Drugs Black Women With Large Waist Circumference Have High Risk of Premature Death M
You May Also Like